Developer docs
API playgroundTry for free, no card

Search company profiles

Psilera

Full company profile

uuid00000vb

Namestring
Psilera
Legal namestring
Psilera Inc.
Websiteurl
psilera.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Psilera is a Tampa, Florida-based, scientist-led biopharmaceutical company founded in 2019 that engineers next-generation neuroplastogen therapies for neuropsychiatric and neurodegenerative disorders. Its lead clinical asset, PSIL-006, is a non-hallucinogenic psilocybin derivative designed for take-home use and insurability, targeting behavioral variant frontotemporal dementia (bvFTD) as the lead indication and Alcohol Use Disorder (AUD) as a secondary program. The company's underlying platform includes a proprietary compound library covering over 1 million novel compounds across six serotonergic families, a novel 4-Br-DMT synthetic chemistry method (published in ACS Omega), and a computational chemistry platform branded "Psilera Third Eye." IP portfolio comprises 13 patents filed with 2 issued from USPTO.

Psilera has assembled a research and development ecosystem spanning NIDA's Designer Drug Research Unit, the University of South Florida Morsani College of Medicine, Hesperos (organ-on-a-chip), and the University of Wisconsin-Madison. The company is pre-revenue and not yet commercial; its business model is structured around pharmaceutical licensing and royalties, government and non-dilutive grant funding, and eventual drug commercialization. A licensing agreement with atai Life Sciences (February 2025) for the DMT patent portfolio provides eligibility for development milestones and royalties on commercial product sales. Cumulative capital raised is approximately $11.3 million across multiple seed rounds, a Series Seed extension, and NIH/Florida High Tech Corridor grants.

The company's go-to-market is sales-led and oriented toward partnership and funding engagement: it presents at industry and investor conferences (Oppenheimer CNS Summit, BIO International, Neuropsychiatric Drug Development Summit) and pursues IND-enabling work targeting first-in-human trials in 2027. Distribution post-approval is anticipated through standard pharmaceutical channels, with PSIL-006 designed for prescription and pharmacy fulfillment. Customer end-markets are patients with bvFTD, AUD, and other treatment-resistant neurological conditions; intermediate "customers" are licensing partners (atai), research collaborators (NIDA, USF, Hesperos), and grant providers (NIH, Florida High Tech Corridor).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTampa, United States
HQ citystring
Tampa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroplastogen therapeutics, psychedelic drug discovery, small molecule drug development, neurodegenerative disease treatments, psilocybin derivative research
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Neurological Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Licensing and Royalties
TypeLicensing Royalties
Description

Revenue from licensing proprietary compounds and patent portfolios to larger pharmaceutical companies, including milestone payments and royalties on commercial product sales. Psilera has a licensing agreement with atai Life Sciences for DMT patent portfolio and is eligible for payments related to certain future development milestones as well as royalties on commercial product sales.

psilera.com
2Drug Development and Commercialization
TypeOne Time License
Description

Revenue from developing and commercializing proprietary neuroplastogen therapeutics. Lead compound PSIL-006 advancing toward first-in-human trials targeting frontotemporal dementia and potentially alcohol use disorder.

pulse2.com
3Government and Non-Dilutive Funding
TypeGrants Donations
Description

Grants from NIH ($2 million for AUD research) and Florida High Tech Corridor ($130,000+) for specific research programs, providing non-dilutive capital for preclinical and clinical development.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1No consumer product pricing available - company is in discovery/clinical stage
ModelOtherBilling cadenceMulti-year contract
Notes

The company is developing prescription neuroplastogen therapeutics that would eventually be sold through pharmaceutical distribution channels. PSIL-006 is designed to be a candidate for take-home use and insurability, suggesting a future commercial product.

psilera.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Psilera is a clinical-stage biopharmaceutical company that discovers and develops proprietary neuroplastogen small molecule therapeutics for neuropsychiatric and neurodegenerative disorders. Its lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia and alcohol use disorder. The company leverages a proprietary synthetic chemistry platform and a compound library of over 1 million novel molecules across six serotonergic families.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • No treatment-limiting side effects (hallucinations) in preclinical testing
+3 more records
Product overview1 text field

Psilera is a scientist-led biopharmaceutical company pioneering next-generation precision neuroscience through engineering novel neuroplastogen therapies. The company operates with a multi-product portfolio centered on its lead clinical asset PSIL-006, a first-in-class non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia. Supporting the core product is an in-house research pipeline featuring six serotonergic compound families with over 1 million novel compounds in their proprietary library, and a novel synthetic chemistry platform enabling expansion into new chemical space beyond the lead compound. The company has 13 patents filed (2 issued from USPTO covering over 1 million novel compounds) and maintains collaborated programs with AtaiBeckley covering DMT patent portfolio.

Product and service1 record
1PSIL-006
CategoryLead Clinical Asset
Description

Lead clinical asset and next-generation psilocybin derivative with non-hallucinogenic profile designed for take-home use and insurability. Advancing toward first-in-human clinical trials in 2027 for behavioral variant frontotemporal dementia (bvFTD) and Alcohol Use Disorder (AUD).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-02-20
Description

Psilera entered a strategic licensing agreement with atai Life Sciences for their DMT patent portfolio. The collaboration covers all granted and pending patents related to DMT and other related psychedelics. Psilera is eligible for payments related to certain future development milestones as well as certain royalties on commercial product sales.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with NIDA's Designer Drug Research Unit on Psilera's novel synthetic platform research published in ACS Omega. The partnership demonstrates ability to develop compounds with new customizable functional groups for neuroplastogen discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration with USF's Morsani College of Medicine since 2019. Research collaborations include preclinical studies on DMT derivatives, small mammal behavior testing with Dr. Dani Gulick, and computational chemistry with Dr. Steven Austin. USF Research Foundation has also invested in Psilera's FTD research.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration since 2025 with drug development leader Hesperos, developers of organ-on-a-chip technology. Hesperos is being used to study disease mechanisms and drug efficacy in preclinical stages of PSIL-006 for frontotemporal dementia.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with Cody Wenthur, PharmD & PhD, Assistant Professor and Director of Psychoactive Pharmaceutical Investigation, since 2021. Collaboration focuses on developing chemical and biological tools to uncover shared molecular deficits in stress management and reward function. Also includes Dr. Christopher Nicholas for clinical development advisory.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health disorders. Already a direct partner via DMT patent licensing and a primary peer as both pursue neuroplastogen and DMT-based therapeutics for psychiatric indications.

TypeDirect peer
Description

Clinical-stage neuroscience company developing non-hallucinogenic neuroplastogens for depression, PTSD, and other CNS conditions. Extremely comparable to Psilera in mechanism, therapeutic area, and non-hallucinogenic differentiation strategy.

TypeDirect peer
Description

Public clinical-stage company pioneering psilocybin therapy for treatment-resistant depression. Competes in the same psychedelic medicine space targeting neuropsychiatric indications with a similarly neuroplasticity-focused scientific thesis.

4MindMed
TypeDirect peer
Description

Public clinical-stage company developing psychedelic-inspired medicines including LSD and MDMA analogs for anxiety, depression, and addiction. Targets similar neuropsychiatric indications and pursues both hallucinogenic and non-hallucinogenic programs.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic-inspired neuroplastogens and breakthrough mental health treatments. Highly comparable in platform approach, target indications, and non-hallucinogenic differentiation.

TypeDirect peer
Description

Public clinical-stage company developing psilocybin-based therapeutics for depression and addiction. Operates in the same psychedelic therapeutics space targeting overlapping indications including alcohol use disorder.

TypeDirect peer
Description

Public clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression. Directly comparable in psychedelic tryptamine chemistry and CNS therapeutic focus.

TypeDirect peer
Description

Public-benefit biotech developing non-hallucinogenic MDMA-inspired medicines (entactogens) for PTSD, depression, and other CNS conditions. Closely comparable to Psilera in pursuing safer, scalable psychedelic-inspired neuroplastogens.

TypeDirect peer
Description

Clinical-stage biotech developing DMT-based therapies for depression. Direct comparable on tryptamine chemistry, serotonin receptor targeting, and psychedelic-inspired therapeutic platform approach.

TypeEmerging player
Description

Emerging biotech developing psychedelic-inspired therapeutics for neurological and inflammatory conditions. Less clinically advanced but pursues overlapping neuroplastogen mechanisms of action with similar CNS indication focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Psilera

Neurological Therapeuticspsilera.com

What Psilera does

Psilera is a Tampa, Florida-based, scientist-led biopharmaceutical company founded in 2019 that engineers next-generation neuroplastogen therapies for neuropsychiatric and neurodegenerative disorders. Its lead clinical asset, PSIL-006, is a non-hallucinogenic psilocybin derivative designed for take-home use and insurability, targeting behavioral variant frontotemporal dementia (bvFTD) as the lead indication and Alcohol Use Disorder (AUD) as a secondary program. The company's underlying platform includes a proprietary compound library covering over 1 million novel compounds across six serotonergic families, a novel 4-Br-DMT synthetic chemistry method (published in ACS Omega), and a computational chemistry platform branded "Psilera Third Eye." IP portfolio comprises 13 patents filed with 2 issued from USPTO.

Psilera has assembled a research and development ecosystem spanning NIDA's Designer Drug Research Unit, the University of South Florida Morsani College of Medicine, Hesperos (organ-on-a-chip), and the University of Wisconsin-Madison. The company is pre-revenue and not yet commercial; its business model is structured around pharmaceutical licensing and royalties, government and non-dilutive grant funding, and eventual drug commercialization. A licensing agreement with atai Life Sciences (February 2025) for the DMT patent portfolio provides eligibility for development milestones and royalties on commercial product sales. Cumulative capital raised is approximately $11.3 million across multiple seed rounds, a Series Seed extension, and NIH/Florida High Tech Corridor grants.

The company's go-to-market is sales-led and oriented toward partnership and funding engagement: it presents at industry and investor conferences (Oppenheimer CNS Summit, BIO International, Neuropsychiatric Drug Development Summit) and pursues IND-enabling work targeting first-in-human trials in 2027. Distribution post-approval is anticipated through standard pharmaceutical channels, with PSIL-006 designed for prescription and pharmacy fulfillment. Customer end-markets are patients with bvFTD, AUD, and other treatment-resistant neurological conditions; intermediate "customers" are licensing partners (atai), research collaborators (NIDA, USF, Hesperos), and grant providers (NIH, Florida High Tech Corridor).

Psilera firmographics

Firmographics
Name
Psilera
Legal name
Psilera Inc.
Website
https://psilera.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Psilera industry classification

Industry
Product category
Neurological Therapeutics
NAICS
Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neuroplastogen therapeutics
  • Psychedelic drug discovery
  • Small molecule drug development
  • Neurodegenerative disease treatments
  • Psilocybin derivative research

Where Psilera is headquartered

Location

Headquarters

HQ city
Tampa
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Psilera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing and Royalties: Revenue from licensing proprietary compounds and patent portfolios to larger pharmaceutical companies, including milestone payments and royalties on commercial product sales. Psilera has a licensing agreement with atai Life Sciences for DMT patent portfolio and is eligible for payments related to certain future development milestones as well as royalties on commercial product sales.
  2. Drug Development and Commercialization: Revenue from developing and commercializing proprietary neuroplastogen therapeutics. Lead compound PSIL-006 advancing toward first-in-human trials targeting frontotemporal dementia and potentially alcohol use disorder.
  3. Government and Non-Dilutive Funding: Grants from NIH ($2 million for AUD research) and Florida High Tech Corridor ($130,000+) for specific research programs, providing non-dilutive capital for preclinical and clinical development.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNo consumer product pricing available - company is in discovery/clinical stage

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Psilera product offering

Product offering

Core offering

Psilera is a clinical-stage biopharmaceutical company that discovers and develops proprietary neuroplastogen small molecule therapeutics for neuropsychiatric and neurodegenerative disorders. Its lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia and alcohol use disorder. The company leverages a proprietary synthetic chemistry platform and a compound library of over 1 million novel molecules across six serotonergic families.

Product overview

Psilera is a scientist-led biopharmaceutical company pioneering next-generation precision neuroscience through engineering novel neuroplastogen therapies. The company operates with a multi-product portfolio centered on its lead clinical asset PSIL-006, a first-in-class non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia. Supporting the core product is an in-house research pipeline featuring six serotonergic compound families with over 1 million novel compounds in their proprietary library, and a novel synthetic chemistry platform enabling expansion into new chemical space beyond the lead compound. The company has 13 patents filed (2 issued from USPTO covering over 1 million novel compounds) and maintains collaborated programs with AtaiBeckley covering DMT patent portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • PSIL-006 Lead clinical asset and next-generation psilocybin derivative with non-hallucinogenic profile designed for take-home use and insurability. Advancing toward first-in-human clinical trials in 2027 for behavioral variant frontotemporal dementia (bvFTD) and Alcohol Use Disorder (AUD).

Quantifiable outcome

  • No treatment-limiting side effects (hallucinations) in preclinical testing
  • +3 more outcomes

Companies that use Psilera

Customer profile

Segments2 records

Ideal customer profiles3 records

Psilera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Psilera partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • atai Life Sciences (AtaiBeckley)coreOEM/ Whitelabel/ Licensing Partner · 20 February 2025Psilera entered a strategic licensing agreement with atai Life Sciences for their DMT patent portfolio. The collaboration covers all granted and pending patents related to DMT and other related psychedelics. Psilera is eligible for payments related to certain future development milestones as well as certain royalties on commercial product sales.
  • National Institute on Drug Abuse (NIDA)coreStrategic or Co-development PartnerCollaboration with NIDA's Designer Drug Research Unit on Psilera's novel synthetic platform research published in ACS Omega. The partnership demonstrates ability to develop compounds with new customizable functional groups for neuroplastogen discovery.
  • University of South FloridacoreStrategic or Co-development PartnerLong-standing collaboration with USF's Morsani College of Medicine since 2019. Research collaborations include preclinical studies on DMT derivatives, small mammal behavior testing with Dr. Dani Gulick, and computational chemistry with Dr. Steven Austin. USF Research Foundation has also invested in Psilera's FTD research.
  • HesperoscoreTechnology or IntegrationCollaboration since 2025 with drug development leader Hesperos, developers of organ-on-a-chip technology. Hesperos is being used to study disease mechanisms and drug efficacy in preclinical stages of PSIL-006 for frontotemporal dementia.
  • University of Wisconsin-MadisonminorStrategic or Co-development PartnerResearch collaboration with Cody Wenthur, PharmD & PhD, Assistant Professor and Director of Psychoactive Pharmaceutical Investigation, since 2021. Collaboration focuses on developing chemical and biological tools to uncover shared molecular deficits in stress management and reward function. Also includes Dr. Christopher Nicholas for clinical development advisory.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Psilera competitors and assessment

Company assessment

Direct peers

  • atai Life Sciences (AtaiBeckley): Public clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health disorders. Already a direct partner via DMT patent licensing and a primary peer as both pursue neuroplastogen and DMT-based therapeutics for psychiatric indications.
  • Delix Therapeutics: Clinical-stage neuroscience company developing non-hallucinogenic neuroplastogens for depression, PTSD, and other CNS conditions. Extremely comparable to Psilera in mechanism, therapeutic area, and non-hallucinogenic differentiation strategy.
  • Compass Pathways: Public clinical-stage company pioneering psilocybin therapy for treatment-resistant depression. Competes in the same psychedelic medicine space targeting neuropsychiatric indications with a similarly neuroplasticity-focused scientific thesis.
  • MindMed: Public clinical-stage company developing psychedelic-inspired medicines including LSD and MDMA analogs for anxiety, depression, and addiction. Targets similar neuropsychiatric indications and pursues both hallucinogenic and non-hallucinogenic programs.
  • Gilgamesh Pharmaceuticals: Clinical-stage biopharmaceutical company developing psychedelic-inspired neuroplastogens and breakthrough mental health treatments. Highly comparable in platform approach, target indications, and non-hallucinogenic differentiation.
  • Cybin: Public clinical-stage company developing psilocybin-based therapeutics for depression and addiction. Operates in the same psychedelic therapeutics space targeting overlapping indications including alcohol use disorder.
  • GH Research: Public clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression. Directly comparable in psychedelic tryptamine chemistry and CNS therapeutic focus.
  • Tactogen: Public-benefit biotech developing non-hallucinogenic MDMA-inspired medicines (entactogens) for PTSD, depression, and other CNS conditions. Closely comparable to Psilera in pursuing safer, scalable psychedelic-inspired neuroplastogens.
  • Small Pharma: Clinical-stage biotech developing DMT-based therapies for depression. Direct comparable on tryptamine chemistry, serotonin receptor targeting, and psychedelic-inspired therapeutic platform approach.

Emerging players

  • Lobe Sciences: Emerging biotech developing psychedelic-inspired therapeutics for neurological and inflammatory conditions. Less clinically advanced but pursues overlapping neuroplastogen mechanisms of action with similar CNS indication focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Psilera social profiles

Digital presence

Psilera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Psilera leadership team

Management profile

Number of profiles

Profiles7 records

Psilera funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Psilera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psilera

What does Psilera do?

Psilera is a clinical-stage biopharmaceutical company that discovers and develops proprietary neuroplastogen small molecule therapeutics for neuropsychiatric and neurodegenerative disorders. Its lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia and alcohol use disorder. The company leverages a proprietary synthetic chemistry platform and a compound library of over 1 million novel molecules across six serotonergic families.

Is Psilera a public or private company?

Psilera is a private company. It is classified as venture growth investor backed and is currently operating.

When was Psilera founded?

Psilera was founded in 2019. It employs 11 to 50 people.

Where is Psilera based?

Psilera is headquartered in Tampa, United States, in the North America region.

How does Psilera make money?

Three revenue lines are on record. Pharmaceutical Licensing and Royalties are the primary driver. The others are drug Development and Commercialization and government and Non-Dilutive Funding.

Who are Psilera's main competitors?

Direct peers on record are atai Life Sciences (AtaiBeckley), Delix Therapeutics, Compass Pathways, MindMed, Gilgamesh Pharmaceuticals, Cybin, GH Research, Tactogen and Small Pharma. Lobe Sciences is listed as an emerging player.

Does Psilera have an API?

No public API is recorded for Psilera.

What industry is Psilera in?

Psilera's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePsilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use DisorderPsilera Inc. initiated Phase 2 of its NIH SBIR grant research into non-hallucinogenic psilocybin derivatives for alcohol use disorder. Phase 1 began in October 2025, and the company expects Phase 1a clinical trials in 2027.StpetecatalystUSF CONNECT renews incubator leaseUSF CONNECT renewed its lease at the Tampa Bay Technology Incubator for five years, covering about $5.5 million. The renewal keeps wet and dry lab space for startups, with Psilera, Modelithics, and PolyMaterials App cited as success stories. The lease reflects USF's push to commercialize university research.PR NewswirePsilera Appoints Neuroscience Veteran Allyson Gage, PhD, as Vice President, Clinical Development to Lead Upcoming Phase 1 Clinical TrialPsilera appointed Allyson Gage, PhD, as Vice President, Clinical Development to lead Phase 1 trials of its lead neuroplastogen PSIL-006. The trial will assess safety, tolerability, and biomarkers for neuropsychiatric conditions. The company also closed an $8.8M seed round and received NIH grant funding.ContractpharmaPsilera Names Allyson Gage VP of Clinical DevelopmentPsilera Inc. appointed Allyson Gage, PhD, as Vice President of Clinical Development, tasked with overseeing the clinical strategy and execution of Phase 1 first-in-human trials of its lead asset PSIL-006. Gage brings over 25 years of experience advancing compounds through FDA IND approval. The Phase 1a trial will assess safety, tolerability and biomarkers for neuropsychiatric conditions including depression, addiction, PTSD and neurodegeneration.PR NewswirePsilera Debuts Novel Synthetic Platform to Aid Discovery of Neuroplastogens in New PublicationPsilera, a biopharmaceutical company, announced a new synthetic chemistry method published in the ACS Omega journal that enables the synthesis of novel neuroplastogens by using 4-Br-DMT as a building block for intermolecular carbon-to-carbon bonding at the 4-position of tryptamines. The research, conducted in collaboration with the National Institute on Drug Abuse's Designer Drug Research Unit, demonstrates the company's ability to expand its patent-protected pipeline beyond its lead compound PSIL-006 into new chemical space. This publication represents a scientific milestone in developing next-generation psychedelic-based therapeutics for targeted therapeutic applications.VC News DailyPsilera Secures $8.8M Seed ExtensionPsilera closed an oversubscribed $8.8 million Series Seed extension led by institutional and strategic investors. The biopharmaceutical company, which develops neuroplastogens, has a pipeline including lead compound PSIL-006.American City Business JournalsTampa's Psilera lands $9M amid psychedelic drug interestTampa-based Psilera closed an oversubscribed $8.8 million series seed round to fund preclinical work on its lead neuroplastogen PSIL-006. The company aims to enter first-in-human studies within roughly 12 months, with additional capital planned for clinical development.Pulse 2.0Psilera: $8.8 Million Seed Round Closed To Advance Neuroplastogen PSIL-006 Into Clinical TrialsPsilera announced the closing of an oversubscribed $8.8 million Series Seed extension funding round led by a syndicate of institutional and strategic investors. The capital will advance the company's lead clinical asset PSIL-006, a first-in-class neuroplastogen, toward first-in-human trials targeted for 2027. The financing positions Psilera to transition from a discovery-stage research company to a clinical-stage organization, alongside a strategic licensing agreement with atai Life Sciences (now AtaiBeckley) for its DMT patent portfolio and up to $2 million in NIH funding.citybizPsilera Raises $8.8M to Advance Non-Hallucinogenic Neuroplastogen Into Human TrialsPsilera closed an oversubscribed $8.8 million seed extension to advance its lead neuroplastogen PSIL-006 toward human trials. The funding supports first-in-human studies targeted for 2027, aiming to reduce hallucinogenic effects and cardiovascular risks. The company also secured NIH funding and a licensing agreement.FinSMEsPsilera Raises $8.8M in Seed FundingPsilera, a Tampa-based biopharmaceutical company, raised $8.8M in seed funding. The company will use the funds to advance its lead compound PSIL-006 toward first-in-human trials in 2027. Backers were not disclosed.